ANRO
ANRO
US02157Q1094
Alto Neuroscience, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 75/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±110.3% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves approx. 1.3x as much as the broader market.

Beta (Market Relation)
1.34x
Above average
Volatility (3Y p.a.)
110.3% p.a.
Fallback
Max Drawdown (3Y)
-91.7%
Fallback
Sharpe Ratio
0.03
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +287%
3 Years 110.3% -91.7% 0.03 —
5 Years — — — —
10 Years — — — —

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
9 ISS Score: 9 / 10
Audit Risk
6 ISS Score: 6 / 10
Board Risk
8 ISS Score: 8 / 10
Short Ratio
8.92
ende